Technical Trend Overview and Price Momentum
Strides Pharma Science Ltd (NSE: 688428), a prominent player in the Pharmaceuticals & Biotechnology sector, currently trades at ₹878.70, slightly up 0.36% from the previous close of ₹875.55. The stock’s intraday range on 20 Feb 2026 spanned ₹865.00 to ₹897.10, indicating moderate volatility. Over the past week and month, the stock has outperformed the Sensex, delivering returns of 1.51% and 1.07% respectively, compared to the Sensex’s negative returns of -1.41% and -0.90% over the same periods.
Despite this short-term outperformance, the year-to-date return stands at -2.62%, marginally better than the Sensex’s -3.19%. However, Strides Pharma’s long-term performance remains impressive, with a 1-year return of 37.38% versus Sensex’s 8.64%, and a remarkable 3-year return of 517.44% compared to Sensex’s 35.24%. This disparity highlights the stock’s strong growth trajectory over extended periods, even as recent momentum shows signs of moderation.
Mixed Signals from Key Technical Indicators
The technical landscape for Strides Pharma is characterised by a blend of mildly bearish and bullish signals across different timeframes and indicators. The Moving Average Convergence Divergence (MACD) indicator, a popular momentum oscillator, remains mildly bearish on both weekly and monthly charts, suggesting that the underlying momentum is still under pressure despite recent gains. This is corroborated by the Know Sure Thing (KST) indicator, which also signals mild bearishness on weekly and monthly timeframes.
Conversely, the daily moving averages have shifted to a mildly bullish stance, indicating that short-term price momentum is gaining some traction. This divergence between daily and longer-term indicators suggests a potential early-stage recovery or consolidation phase rather than a decisive trend reversal.
The Relative Strength Index (RSI), often used to gauge overbought or oversold conditions, currently shows no clear signal on weekly or monthly charts, hovering in a neutral zone. This neutrality implies that the stock is neither overextended nor deeply undervalued technically, leaving room for directional movement based on upcoming market catalysts.
Bollinger Bands present a mixed picture: weekly readings are mildly bearish, signalling some downward pressure or volatility compression, while monthly bands are bullish, hinting at a longer-term expansion in price range and potential upward momentum. This contrast further emphasises the stock’s current technical indecision.
Other volume-based indicators such as On-Balance Volume (OBV) are mildly bearish on the weekly scale but show no trend on the monthly scale, indicating that volume flows have not decisively confirmed price movements recently. Dow Theory analysis also reports no clear trend on weekly or monthly charts, reinforcing the view of a market in consolidation.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
MarketsMOJO Grade Downgrade and Its Implications
On 16 Feb 2026, MarketsMOJO downgraded Strides Pharma’s Mojo Grade from Hold to Sell, reflecting a more cautious stance amid the mixed technical signals and evolving market conditions. The current Mojo Score stands at 48.0, which is below the neutral 50 mark, reinforcing the sell recommendation. The Market Cap Grade remains at 3, indicating a mid-tier market capitalisation relative to peers.
This downgrade suggests that while the stock has demonstrated strong historical returns, near-term technical momentum and fundamental factors may not support aggressive buying. Investors should weigh this cautious outlook against the stock’s resilience and sector dynamics before making allocation decisions.
Comparative Performance and Sector Context
Strides Pharma operates within the Pharmaceuticals & Biotechnology sector, a space often characterised by volatility linked to regulatory developments, research outcomes, and global health trends. Despite the recent technical uncertainty, the company’s long-term outperformance relative to the Sensex underscores its competitive positioning and growth potential.
However, the current mildly bullish daily moving averages juxtaposed with bearish weekly and monthly momentum indicators suggest that the stock may be in a transitional phase. Investors should monitor upcoming quarterly results, pipeline updates, and sector news to better gauge the sustainability of any upward momentum.
Holding Strides Pharma Science Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaways and Outlook
For investors tracking Strides Pharma Science Ltd, the current technical landscape advises a balanced approach. The mildly bullish daily moving averages offer some optimism for short-term gains, but the prevailing bearishness in weekly and monthly momentum indicators calls for caution. The absence of strong RSI signals and mixed Bollinger Band readings further complicate the outlook.
Given the MarketsMOJO downgrade to Sell and the stock’s recent sideways to mildly bullish trend shift, investors should consider risk management strategies, including setting stop-loss levels and monitoring volume trends closely. The stock’s strong long-term returns relative to the Sensex remain a positive backdrop, but near-term price action may be susceptible to volatility and sector-specific developments.
Ultimately, Strides Pharma’s technical parameters suggest a stock in consolidation with potential for moderate upside, but not without risks. Close attention to upcoming earnings, regulatory news, and broader market trends will be essential for informed decision-making.
Summary of Technical Indicator Signals
- MACD: Mildly Bearish on Weekly and Monthly charts
- RSI: Neutral, no clear signal on Weekly and Monthly charts
- Bollinger Bands: Mildly Bearish Weekly, Bullish Monthly
- Moving Averages: Mildly Bullish on Daily chart
- KST: Mildly Bearish on Weekly and Monthly charts
- Dow Theory: No clear trend on Weekly and Monthly charts
- OBV: Mildly Bearish Weekly, No trend Monthly
These mixed signals underscore the importance of a cautious, data-driven approach to trading or investing in Strides Pharma Science Ltd at this juncture.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
